

## IAG933

### YAP/TAZ-TEAD


YAP/TAZ-TEAD PPI inhibitor

Ph. I for mesothelioma

from virtual screening, SBDD, and property-based opt.

*Nat. Cancer*, April 2024

NOVARTIS BIOMEDICAL RESEARCH, BASEL, CH



## HRO761

### WRN helicase


WRN helicase allosteric inhibitor

Ph. I for MSI-high solid tumors

from HTS, SBDD, and lipE-guided opt.

*Nature*, April 2024

NOVARTIS BIOMEDICAL RESEARCH, BASEL, CH



## RMC-6236

### pan-RAS(ON)


macrocyclic pan-RAS(ON) noncovalent inhibitor

Ph. I/II for RAS-mutated lung cancers

structure-guided design from the natural product, sanglifehrin A

*Cancer Discov.*, April 2024

REVOLUTION MEDICINES, REDWOOD CITY, CA



## tavapadon

### D<sub>1</sub>/D<sub>5</sub> receptors


D<sub>1</sub>/D<sub>5</sub> receptors partial agonist

Ph. III for Parkinson's disease

hit identification method undisclosed

*Press Release*, April 2024

Pfizer, NY / CERVEL Therapeutics, MA



## KT-333

### STAT3


VHL-based STAT3 degrader

Ph. I for lymphoma, leukemia, solid tumors

from known inhibitors

*Press Release*, April 2024

KYMERA Therapeutics, Watertown, MA



## TNG908

### PRMT5


brain-penetrant PRMT5:MTA complex inhibitor

Ph. I/II for solid tumors

HTS, LBDD, and SBDD

*J. Med. Chem.*, April 2024

Tango Therapeutics, Boston, MA



## NST-628

### RAF-MEK


brain-penetrant (pan-RAF)-MEK molecular glue

Ph. I for solid tumors

deliberate opt. of dual phospho-MEK/ERK inhibition, CNS penetration, and ADME/DMPK

*Cancer Discov.*, April 2024

Nested Therapeutics, Cambridge, MA



## CVN293

### KCNK13


brain-penetrant KCNK13 inhibitor

preclinical for neurodegenerative disorders

from HTS, metabolic stab., and PK opt

*ACS Med. Chem. Lett.*, April 2024

Cerevance Limited, Cambridge, UK



## BDTX-1535

### EGFR


brain-penetrant EGFR "MasterKey" inhibitor

Ph. I/II for glioma, glioblastoma, lung cancer

hit identification method undisclosed

*Press Release*, April 2024

Black Diamond Therapeutics, Cambridge, MA



## sovleplenib

### Syk

Syk inhibitor

Ph. III for autoimmune hemolytic anemia, primary immune thrombocytopenia

from internal library screening, SAR, and PK opt.

*ACS Med. Chem. Lett.*, April 2024

Hutchmed Limited, Shanghai, CN